SUPPLEMENTARY FUNDING OFFER FOR THE MRC UNIT, THE GAMBIA AT LSHTM (resource to support a clinical trial of Hydroxychloroquine and Azithromycin, studies on the transmission and antibody dynamics to SARS-CoV-2 infection, and to further support
Lead Research Organisation:
London Sch of Hygiene & Tropic. Medicine
Department Name: UNLISTED
Abstract
Abstracts are not currently available in GtR for all funded research. This is normally because the abstract was not required at the time of proposal submission, but may be because it included sensitive information such as personal details.
Technical Summary
This £4.4m award provides resource to support a clinical trial of Hydroxychloroquine and Azithromycin, studies on the transmission and antibody dynamics to SARS-CoV-2 infection, and to further support surveillance activities funded by BMGF.
Including
PaTS-COVID CLINICAL TRIAL – led by Professor Beate Kampmann with an end date 31/12/2023
The TransVir project – led by Dr Anna Roca with an end date 30/06/2023
Including
PaTS-COVID CLINICAL TRIAL – led by Professor Beate Kampmann with an end date 31/12/2023
The TransVir project – led by Dr Anna Roca with an end date 30/06/2023
Publications
Bonell A
(2021)
Impact of Personal Cooling on Performance, Comfort and Heat Strain of Healthcare Workers in PPE, a Study From West Africa.
in Frontiers in public health
Brotherton H
(2020)
Dexamethasone for COVID-19: data needed from randomised clinical trials in Africa.
in The Lancet. Global health
Diallo BA
(2022)
Clinical research on COVID-19: perceptions and barriers to participation in The Gambia.
in BMJ global health
Jarju S
(2024)
High SARS-CoV-2 incidence and asymptomatic fraction during Delta and Omicron BA.1 waves in The Gambia.
in Nature communications
| Description | Ivermectin, a potential treatment for COVID-19 patients, did not show any therapeutic effect. We also investigated aspirin and high dose corticosteroids as potential treatment. However, the number of patients recruited were lower than expected. |
| Exploitation Route | Outcomes show that several candidate treatments for COVID-19 were not efficacious. |
| Sectors | Pharmaceuticals and Medical Biotechnology |
| Description | The trial investigated the treatment of several treatment option for mild and severe Covid-19. Results contributed to define treatment guidelines for these patients. |
| First Year Of Impact | 2022 |
| Sector | Pharmaceuticals and Medical Biotechnology |
| Impact Types | Policy & public services |
| Description | COVID-19 STRATEGIC COORDINATION MEETING |
| Geographic Reach | National |
| Policy Influence Type | Implementation circular/rapid advice/letter to e.g. Ministry of Health |
| Impact | Coordination of Covid-19 public health interventions. |
| Description | Collaboration with Ministry of Health Gambia |
| Organisation | Government of The Gambia |
| Department | Ministry of Health Gambia |
| Country | Gambia |
| Sector | Public |
| PI Contribution | Provision of diagnostic facilities for SARS-CoV-2. Training staff at National Public Health Laboratories and set up of the diagnostic facilities. Participation into several committees for Covid-19 control in the Gambia. |
| Collaborator Contribution | Management of the Coivid-19 pandemic. |
| Impact | Publications Policies documents for the control of Covid-19 pandemic in The Gambia |
| Start Year | 2020 |